We've covered the French Sunshine Act, which requires French
pharmaceutical companies to disclose their links to healthcare
extensively over the past few years and most recently
here. France on the whole, however, has been lagging behind
many other countries when it comes to anti-corruption laws. It
looks like that's about to change in ways that could have
considerable impact for life sciences companies operating in the
France has started examining draft legislation which proposes
creating a national anti-corruption agency to replace the Central
Service for the Prevention of Corruption (SCPC). The SCPC currently
has neither investigative nor fining powers. The new agency would
be in charge of investigating whistle-blower reports, carrying out
related investigations, and monitoring the implementation of
specific compliance programs. It would also have the power to
The draft legislation proposes several other key changes,
The creation of a national register of lobbyists, similar to
what the French Sunshine Act requires from the pharmaceutical
industry. Interest group representatives would have to disclose
their identity and the scope of their lobbying activities to the
High Authority for Transparency in Public Life.
A legal status for whistle-blowers that would prohibit any
dismissal or discrimination in cases where their statements had
been relied on by the national anti-corruption agency.
The creation of a new criminal offense for failure to put into
place a compliance program (similar to the UK Bribery Act).
A considerable increase in fines.
The option for French companies convicted of corruption to
negotiate a fine with the public prosecutor instead of being
Inquests are something which affect a vast range of NHS and private organisations, as well as individual clinicians, and so we provide a brief overview of recent developments as well as a couple of key potential changes to come.
Le 28 janvier dernier, le Président du Tribunal de grande instance de Nanterre, statuant en référé, a accordé des dommages et intérêts au titre du préjudice d'anxiété à certaines victimes du Mediator dans trois jugements.
The Turkish Competition Board has launched an investigation into the alleged blocking by the Turkish Pharmacists Union of "named patient sales" by pharmaceutical warehouses.
Some comments from our readers… “The articles are extremely timely and highly applicable” “I often find critical information not available elsewhere” “As in-house counsel, Mondaq’s service is of great value”
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).